OVERVIEW

Evidence Based Treatment - T2D and Heart Failure is organized by PharmCon, Inc.

Release Date: Tuesday, September 22, 2020
Offline Date: Wednesday, September 22, 2021
ACPE Expiration Date: Saturday, September 2, 2023

Overview:
Co-morbidities are common in patients with heart failure, with evidence showing over half of these patients suffer from an additional chronic disease state. One of those disease states is diabetes. The inter-relationship between heart failure and diabetes has been well documented with estimations of 20-40% of patients with heart failure also having diabetes. Diabetes is also an independent risk factor for developing heart failure and patients are up to two times more likely to develop heart failure than someone without diabetes. We developed this activity to address the potential gaps in pharmacist knowledge of the importance of guideline-directed medical therapy and the impact on heart failure-related outcomes and the expanded indications of previously approved glucose-lowering therapies in patients with type 2 diabetes and established cardiovascular disease.

Learning Objectives:
Pharmacist, Pharmacy Technician and Nurse:
• Describe a patient with heart failure who would benefit from the addition of a SGLT2 inhibitor to their medication therapy.
• Outline the guideline directed medical therapy for patients with co-morbid diabetes and cardiovascular disease
• Compare and contrast evidence-based treatment options that optimize glycemic control and reduce cardiovascular events in patients with co-morbid type 2 diabetes and cardiovascular disease and in those with heart failure alone.
• Identify appropriate strategies to communicate the evidence-based treatment approaches for patients with comorbid diabetes and heart failure to both patients and members of the healthcare team.